Forward-looking statements within the meaning of the Private Securities Litigation Reform Act reptile dysfunction.

The statements in this press release about future expectations concerning clinical trials and drug approvals are conditions or strategies and other business matters, forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements involve a number of assumptions, risks and uncertainties that may change over time reptile dysfunction . Product candidates specific GenVec; Factors that could cause actual the forward-looking disputed by the forward-looking statements or historical experience of to risks and uncertainties, including the financial condition of GenVec and its ability to raise capital to clinical programs and funding future operations is in the early stages of development, uncertainties and unexpected results and related analyzes relating to clinical studies GenVec ‘s product candidates , the timing, the amount and availability of revenues from GenVec government funded vaccination programs, the timing and content of future FDA regulatory actions related to GenVec or its product candidates; find GenVec ability to staff or to market their product candidates, Moreover,ty of patent protection for GenVec ‘s product candidates and its ability without infringing the without infringing the patent rights of others. Furthermore Certain statements in this press release address survival data on an interim analysis clinical trial results TNFerade in locally advanced pancreatic cancer based. There is no assurance that the future analyzes will confirm this first interim report. Moreover, the survival. Data only one of many factors to consider that the Food and Drug Administration, if you TNFerade for the registration and approval can not be guaranteed.

GenVecGenVec today announced top-line results from an interim analysis of its ongoing Phase III pancreatic cancer trial with TNFerade in patients with locally advanced pancreatic cancer. This preliminary analysis of overall survival, according to the 92nd Death was performed, was designed to determine whether the trial continued and found the period originally estimated.

Are three different lila sweet potatoes were used had been various amounts of anthocyanins for the project. To quantification the quantity in each potato, Lim is extracted pigments of from the vegetable and injected it in of an HPLC MS analysis which she said is to a method separated components.